Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India.

ABSTRACT:

Background

This post hoc analysis evaluated the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) from India.

Methods

Changes from baseline in HbA1c, fasting plasma glucose (FPG), body weight, and blood pressure (BP) with canagliflozin 100 and 300 mg were evaluated in a subgroup of patients from India (n = 124) from 4 randomized, double-blind, placebo- and active-controlled, Phase 3 studies (N = 2313; Population 1). Safety was assessed based on adverse event (AE) reports in these patients and in a broader subgroup of patients from India (n = 1038) from 8 randomized, double-blind, placebo- and active-controlled, Phase 3 studies (N = 9439; Population 2).

Results

Reductions in HbA1c with ca

SUBMITTER: Prasanna Kumar KM 

PROVIDER: S-EPMC4855968 | biostudies-literature | 2016 May-Jun

REPOSITORIES: biostudies-literature